+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Doxorubicin Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Drug Formulation, Application, and Distribution Channel

  • PDF Icon

    Report

  • 199 Pages
  • July 2022
  • Region: Global
  • The Insight Partners
  • ID: 5646816
UP TO OFF until Mar 15th 2023
The global doxorubicin market is projected to reach US$ 1,983.40 million by 2028 from US$ 1,390.64 million in 2022; it is expected to register a CAGR of 6.1% from 2022 to 2028.

Increasing prevalence of cancer and increasing preference of chemotherapy are driving the global doxorubicin market growth. However, the potential side-effects associated with doxorubicin is hampering the global doxorubicin market growth.

Doxorubicin belongs to the anthracycline family and is widely used for the treatment of malignancies such as breast, lung, multiple myeloma, ovarian, kidney, liver, sarcoma, and others. The product is used in the patients with cancer whose disease has progressed or recurred after chemotherapy. Cancer is a leading cause of death globally. According to the World Health Organization (WHO), cancer was the first leading cause of death in people below 70 years in 183 countries and the fourth major cause of death among the population of all ages in 123 countries worldwide in 2019. In addition, as per the data published by the WHO in March 2021, different cancer types will have caused ~10 million deaths in 2020. The increasing prevalence of cancer has burdened healthcare systems worldwide, bolstering the demand for chemotherapy. Doxorubicin is one of the primary drugs used as first-line treatment in chemotherapy. The drug is used to cause regression in disseminated neoplastic diseases like breast, ovarian, transitional cell bladder, thyroid, gastric, acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms' tumor, neuroblastoma, soft tissue and bone sarcomas, Hodgkin's disease, malignant lymphoma, and bronchogenic carcinomas, in which the small cell histologic type. The drug is also recommended as adjuvant therapy in women who have had primary breast cancer removed and have axillary lymph node involvement.

Furthermore, government funding for cancer prevention in various countries offers significant growth opportunities for the global doxorubicin market. For Instance, in June 2020, the National Institutes of Health granted nearly US$ 3.5 million to the University of Missouri School of Medicine to study a pre-treatment for chemotherapy that could protect cancer patients from therapy-induced heart problems. Thus, with rising cancer prevalence and increasing government support as funding, guidance, and assistance, emerging countries are providing significant growth opportunities to manufacturers operating in the line doxorubicin drug market.

A few of the recent developments related to doxorubicin are mentioned below:
- In October 2021, Padagis received FDA approval and launched an AB-rated generic version of Doxil (Doxorubicin Liposome Injection) through its partnership with Ayana Pharma Ltd.
- In September 2020, Zydus Cadila received final approval for the commercialization of its generic Doxorubicin Hydrochloride Liposome Injection by the US FDA for cancer treatment in the US.

- In September 2018, Hikma Pharmaceuticals USA Inc., a subsidiary of Hikma Pharmaceuticals PLC, launched Adriamycin (DOXOrubicin HCl) for Injection as a part of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node association following resection of primary breast cancer.
- In May 2018, Dr. Reddy's received approval from US FDA to launch Doxorubicin Hydrochloride Liposome Injection in the US market. The US FDA approval resulted from extensive collaboration with partner NatcoPharma Limited on R&D and manufacturing capabilities.

Thus, approval of generic substitution for frequently used chemotherapy drugs, such as doxorubicin, in treating common cancers has a vast potential to increase significant cost savings and rising access to cancer treatments in low- and middle-income countries.

Moreover, the COVID-19 pandemic disrupted the socioeconomic conditions of various countries worldwide. The cost of overall healthcare is surging significantly in North America. The US health system incurred a direct cost of US$ 5.3 billion in 2020. The healthcare system contributed US$ 60 billion in addition to the overall annual costs of the country in 2020. Over 40% of the population in North America canceled their appointments in 2020, and 13% reported that they needed care but did not either schedule or receive care. The COVID-19 pandemic altered economic conditions and social behaviors in North American countries. Containment measures enacted by governments to mitigate the spread of disease changed the US healthcare service delivery pattern. According to the Department of Emergency Medicine, in many cities across the country, emergency department (ED) visits decreased by ~40% in 2020. Moreover, outpatient appointments and elective treatments were postponed or replaced by telemedicine practices

According to Cancer Statistics, 2022, published in the American Cancer Society’s journal, data from 2015 to 2019 indicated a 0.5% annual increase in female breast cancer. At the same time, the incidence of prostate cancer remained stable. Thus, the increasing number of cancer patients worldwide is projected to drive global doxorubicin market growth.

Based on Drug Formulation, the global doxorubicin market is segmented into lyophilized powder and doxorubicin injection. In 2022, the lyophilized powder segment accounted for a greater market share. The market position of this segment is increasing prevalence of cancer and rising preference of chemotherapy.

The global doxorubicin market, based on application, has been categorized into lung cancer, sarcoma, breast cancer, multiple myeloma, ovarian cancer, kidney cancer, leukemia, liver cancer, and others. The breast cancer segment is likely to dominate the market in 2022. The segment is expected to grow in the upcoming forecast period due to the increasing prevalence of breast cancer treatment using chemotherapy

The global doxorubicin market, based on distribution channel, has been categorized into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment is likely to hold the largest share of the market in 2022. The segment is expected to grow in the upcoming forecast period due to rising number of chemotherapy procedures in the hospitals.

The World Health Organization (WHO), National Healthcare Service (NHS), Centers for Disease Control and Prevention (CDC), Canadian Partnership Against Cancer (CPAC), United States Cancer Statistics (USCS), Globocan Statistics 2020, World Bank Data, North American Free Trade Agreement (NAFTA), and Australian Institute of Health and Welfare are among the major secondary sources referred to while preparing the report on the global doxorubicin market.


Frequently Asked Questions about the Global Doxorubicin Market

What is the estimated value of the Global Doxorubicin Market?

The Global Doxorubicin Market was estimated to be valued at $1390.64 million in 2022.

What is the growth rate of the Global Doxorubicin Market?

The growth rate of the Global Doxorubicin Market is 6.1%, with an estimated value of $1983.4 million by 2028.

What is the forecasted size of the Global Doxorubicin Market?

The Global Doxorubicin Market is estimated to be worth $1983.4 million by 2028.

Who are the key companies in the Global Doxorubicin Market?

Key companies in the Global Doxorubicin Market include Accord Healthcare, Cipla Inc., Dr. Reddy's Laboratories, Meiji Holdings Co., Ltd., Janssen Pharmaceuticals (Johnson and Johnson Services, Inc.), Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd and Zydus Cadila.

Table of Contents

1. Introduction
1.1 Scope of the Study
1.2 Research Report Guidance
1.3 Market Segmentation
1.3.1 Global Doxorubicin Market - By Drug Formulation
1.3.2 Global Doxorubicin Market - By Application
1.3.3 Global Doxorubicin Market - By Distribution Channel
1.3.4 Global Doxorubicin Market - By Geography
2. Doxorubicin market - Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Global Doxorubicin Market - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America - PEST Analysis
4.2.2 Europe - PEST Analysis
4.2.3 Asia Pacific - PEST Analysis
4.2.4 Middle East & Africa - PEST Analysis
4.2.5 South & Central America - PEST Analysis
4.3 Expert Opinion
5. Doxorubicin Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Prevalence of Cancer
5.1.2 Increasing Preference for Chemotherapy
5.2 Market Restraints
5.2.1 Potential Side-effects Associated with Doxorubicin
5.3 Market Opportunities
5.3.1 Increasing Government Funding, Guidance, and Technical Assistance for Cancer Prevention
5.4 Future Trends
5.4.1 Increasing Approval of Generic Products
5.5 Impact Analysis
6. Doxorubicin Market- Global Analysis
6.1 Global Doxorubicin Market Revenue Forecast and Analysis
6.1.1 Global Doxorubicin Market Revenue Forecast and Analysis
6.1.2 Global Doxorubicin Market- Market Potential Analysis, By Region
6.2 Market Share Analysis
6.2.1 Company Analysis
6.2.2 Growth Strategy Analysis
6.2.3 Market Positioning of Key Players in Doxorubicin Market
6.2.3.1 Janssen Pharmaceuticals (Johnson and Johnson Services, Inc.)
6.2.3.2 Pfizer Inc.
7. Global Doxorubicin Market Revenue and Forecast to 2028 - by Drug Formulation
7.1 Overview
7.2 Global Doxorubicin Market Share, By Drug Formulation 2022 & 2028 (%)
7.3 Lyophilized Powder
7.3.1 Overview
7.3.2 Lyophilized Powder: Doxorubicin Market Revenue and Forecast To 2028 (US$ Million)
7.4 Doxorubicin Injection
7.4.1.1 Overview
7.4.2 Doxorubicin Injection: Doxorubicin Market Revenue and Forecast To 2028 (US$ Million)
8. Global Doxorubicin Market Revenue and Forecast to 2028 - by Application
8.1 Overview
8.2 Global Doxorubicin Market Share, By Application 2022 & 2028 (%)
8.3 Breast Cancer
8.3.1.1 Overview
8.3.2 Breast Cancer: Doxorubicin Market Revenue and Forecast To 2028 (US$ Million)
8.4 Kidney Cancer
8.4.1.1 Overview
8.4.2 Kidney Cancer: Doxorubicin Market Revenue and Forecast To 2028 (US$ Million)
8.5 Liver Cancer
8.5.1.1 Overview
8.5.2 Liver Cancer: Doxorubicin Market Revenue and Forecast To 2028 (US$ Million)
8.6 Sarcoma
8.6.1.1 Overview
8.6.2 Sarcoma: Doxorubicin Market Revenue and Forecast To 2028 (US$ Million)
8.7 Ovarian Cancer
8.7.1.1 Overview
8.7.2 Ovarian Cancer: Doxorubicin Market Revenue and Forecast To 2028 (US$ Million)
8.8 Lung Cancer
8.8.1 Overview
8.8.2 Lung Cancer: Doxorubicin Market Revenue and Forecast To 2028 (US$ Million)
8.9 Leukemia
8.9.1.1 Overview
8.9.2 Leukemia: Doxorubicin Market Revenue and Forecast To 2028 (US$ Million)
8.10 Multiple Myeloma
8.10.1.1 Overview
8.10.2 Multiple Myeloma: Doxorubicin Market Revenue and Forecast To 2028 (US$ Million)
8.11 Others
8.11.1.1 Overview
8.11.2 Others: Doxorubicin Market Revenue and Forecast To 2028 (US$ Million)
9. Global Doxorubicin Market Revenue and Forecast to 2028 - by Disribution Channel
9.1 Overview
9.2 Global Doxorubicin Market Share, By Disribution Channel 2022 & 2028 (%)
9.3 Hospital Pharmacy
9.3.1 Overview
9.3.2 Hospital Pharmacy: Doxorubicin Market Revenue and Forecast To 2028 (US$ Million)
9.4 Retail Pharmacy
9.4.1.1 Overview
9.4.2 Retail Pharmacy: Doxorubicin Market Revenue and Forecast To 2028 (US$ Million)
9.5 Online Pharmacy
9.5.1.1 Overview
9.5.2 Online Pharmacy: Doxorubicin Market Revenue and Forecast To 2028 (US$ Million)
10. Global Doxorubicin Market Revenue and Forecast to 2028- by Geography
10.1 North America: Doxorubicin Market Revenue and Forecasts To 2028
10.1.1 Overview
10.1.2 North America: Doxorubicin Market - Revenue and Forecast to 2028 (US$ Million)
10.1.3 North America: Doxorubicin Market, by Drug Formulation, 2019-2028 (US$ Million)
10.1.4 North America: Doxorubicin Market, by Application, 2019-2028 (US$ Million)
10.1.5 North America: Doxorubicin Market, by Distribution Channel, 2019-2028 (US$ Million)
10.1.6 North America: Doxorubicin Market, by Country, 2022 & 2028 (%)
10.1.6.1 US: Doxorubicin Market - Revenue and Forecast to 2028 (US$ Million)
10.1.6.1.1 Overview
10.1.6.1.2 US: Doxorubicin Market - Revenue and Forecast to 2028 (US$ Million)
10.1.6.1.3 US: Doxorubicin Market, by Drug Formulation, 2019-2028 (US$ Million)
10.1.6.1.4 US: Doxorubicin Market, by Application, 2019-2028 (US$ Million)
10.1.6.1.5 US: Doxorubicin Market, by Distribution Channel, 2019-2028 (US$ Million)
10.1.6.2 Canada: Doxorubicin Market - Revenue and Forecast to 2028 (US$ Million)
10.1.6.2.1 Overview
10.1.6.2.2 Canada: Doxorubicin Market - Revenue and Forecast to 2028 (US$ Million)
10.1.6.2.3 Canada: Doxorubicin Market, by Drug Formulation, 2019-2028 (US$ Million)
10.1.6.2.4 Canada: Doxorubicin Market, by Application, 2019-2028 (US$ Million)
10.1.6.2.5 Canada: Doxorubicin Market, by Distribution Channel, 2019-2028 (US$ Million)
10.1.6.3 Mexico: Doxorubicin Market - Revenue and Forecast to 2028 (US$ Million)
10.1.6.3.1 Overview
10.1.6.3.2 Mexico: Doxorubicin Market - Revenue and Forecast to 2028 (US$ Million)
10.1.6.3.3 Mexico: Doxorubicin Market, by Drug Formulation, 2019-2028 (US$ Million)
10.1.6.3.4 Mexico: Doxorubicin Market, by Application, 2019-2028 (US$ Million)
10.1.6.3.5 Mexico: Doxorubicin Market, by Distribution Channel, 2019-2028 (US$ Million)
10.2 Europe Doxorubicin Market, Revenue and Forecast to 2028
10.2.1 Overview
10.2.2 Europe Doxorubicin Market, Revenue and Forecast to 2028 (US$ Mn)
10.2.3 Europe Doxorubicin Market Revenue and Forecast to 2028, by Drug Formulation (US$ Mn)
10.2.4 Europe Doxorubicin Market, Revenue and Forecast to 2028, by Application (US$ Mn)
10.2.5 Europe Doxorubicin Market Revenue and Forecast to 2028, by Distribution Channel (US$ Mn)
10.2.6 Europe Doxorubicin Market, Revenue and Forecast to 2028, by Country (%)
10.2.6.1 UK Doxorubicin Market Revenue and Forecasts to 2027 (US$ Mn)
10.2.6.1.1 UK Doxorubicin Market, Revenue and Forecast to 2028 (US$ Mn)
10.2.6.1.2 UK Doxorubicin Market Revenue and Forecast to 2028, by Drug Formulation (US$ Mn)
10.2.6.1.3 UK Doxorubicin Market, Revenue and Forecast to 2028, by Application (US$ Mn)
10.2.6.1.4 UK Doxorubicin Market Revenue and Forecast to 2028, by Distribution Channel (US$ Mn)
10.2.6.2 Germany Doxorubicin Market Revenue and Forecasts to 2028 (US$ Mn)
10.2.6.2.1 Germany Doxorubicin Market, Revenue and Forecast to 2028 (US$ Mn)
10.2.6.2.2 Germany Doxorubicin Market Revenue and Forecast to 2028, by Drug Formulation (US$ Mn)
10.2.6.2.3 Germany Doxorubicin Market, Revenue and Forecast to 2028, by Application (US$ Mn)
10.2.6.2.4 Germany Doxorubicin Market Revenue and Forecast to 2028, by Distribution Channel (US$ Mn)
10.2.6.3 France Doxorubicin Market Revenue and Forecasts to 2028 (US$ Mn)
10.2.6.3.1 France Doxorubicin Market, Revenue and Forecast to 2028 (US$ Mn)
10.2.6.3.2 France Doxorubicin Market Revenue and Forecast to 2028, by Drug Formulation (US$ Mn)
10.2.6.3.3 France Doxorubicin Market, Revenue and Forecast to 2028, by Application (US$ Mn)
10.2.6.3.4 France Doxorubicin Market Revenue and Forecast to 2028, by Distribution Channel (US$ Mn)
10.2.6.4 Italy Doxorubicin Market Revenue and Forecasts to 2028 (US$ Mn)
10.2.6.4.1 Italy Doxorubicin Market, Revenue and Forecast to 2028 (US$ Mn)
10.2.6.4.2 Italy Doxorubicin Market Revenue and Forecast to 2028, by Drug Formulation (US$ Mn)
10.2.6.4.3 Italy Doxorubicin Market, Revenue and Forecast to 2028, by Application (US$ Mn)
10.2.6.4.4 Italy Doxorubicin Market Revenue and Forecast to 2028, by Distribution Channel (US$ Mn)
10.2.6.5 Spain Doxorubicin Market Revenue and Forecasts to 2028 (US$ Mn)
10.2.6.5.1 Spain Doxorubicin Market, Revenue and Forecast to 2028 (US$ Mn)
10.2.6.5.2 Spain Doxorubicin Market Revenue and Forecast to 2028, by Drug Formulation (US$ Mn)
10.2.6.5.3 Spain Doxorubicin Market, Revenue and Forecast to 2028, by Application (US$ Mn)
10.2.6.5.4 Spain Doxorubicin Market Revenue and Forecast to 2028, by Distribution Channel (US$ Mn)
10.2.6.6 Rest of Europe Doxorubicin Market Revenue and Forecasts to 2028 (US$ Mn)
10.2.6.6.1 Rest of Europe Doxorubicin Market, Revenue and Forecast to 2028 (US$ Mn)
10.2.6.6.2 Rest of Europe Doxorubicin Market Revenue and Forecast to 2028, by Drug Formulation (US$ Mn)
10.2.6.6.3 Rest of Europe Doxorubicin Market, Revenue and Forecast to 2028, by Application (US$ Mn)
10.2.6.6.4 Rest of Europe Doxorubicin Market Revenue and Forecast to 2028, by Distribution Channel (US$ Mn)
10.3 Asia Pacific: Doxorubicin Market
10.3.1 Overview
10.3.2 Asia Pacific: Doxorubicin Market - Revenue and Forecast to 2028 (US$ Million)
10.3.3 Asia Pacific: Doxorubicin Market, By Drug Formulation, 2019-2028 (US$ Million)
10.3.4 Asia Pacific: Doxorubicin Market, by Application, 2019-2028 (US$ Million)
10.3.5 Asia Pacific: Doxorubicin Market, By Distribution Channel, 2019-2028 (US$ Million)
10.3.6 Asia Pacific: Doxorubicin Market, by Country, 2022 & 2028 (%)
10.3.6.1 China: Doxorubicin Market - Revenue and Forecast to 2028 (US$ Million)
10.3.6.1.1 China: Doxorubicin Market - Revenue and Forecast to 2028 (US$ Million)
10.3.6.1.2 China: Doxorubicin Market, By Drug Formulation, 2019-2028 (US$ Million)
10.3.6.1.3 China: Doxorubicin Market, by Application, 2019-2028 (US$ Million)
10.3.6.1.4 China: Doxorubicin Market, By Distribution Channel, 2019-2028 (US$ Million)
10.3.6.2 Japan: Doxorubicin Market - Revenue and Forecast to 2028 (US$ Million)
10.3.6.2.1 Japan: Doxorubicin Market - Revenue and Forecast to 2028 (US$ Million)
10.3.6.2.2 Japan: Doxorubicin Market, By Drug Formulation, 2019-2028 (US$ Million)
10.3.6.2.3 Japan: Doxorubicin Market, By Application, 2019-2028 (US$ Million)
10.3.6.2.4 Japan: Doxorubicin Market, By Distribution Channel, 2019-2028 (US$ Million)
10.3.6.3 India: Doxorubicin Market - Revenue and Forecast to 2028 (US$ Million)
10.3.6.3.1 India: Doxorubicin Market - Revenue and Forecast to 2028 (US$ Million)
10.3.6.3.2 India: Doxorubicin Market, By Drug Formulation, 2019-2028 (US$ Million)
10.3.6.3.3 India: Doxorubicin Market, By Application, 2019-2028 (US$ Million)
10.3.6.3.4 India: Doxorubicin Market, By Distribution Channel, 2019-2028 (US$ Million)
10.3.6.4 South Korea: Doxorubicin Market - Revenue and Forecast to 2028 (US$ Million)
10.3.6.4.1 South Korea: Doxorubicin Market - Revenue and Forecast to 2028 (US$ Million)
10.3.6.4.2 South Korea: Doxorubicin Market, By Drug Formulation, 2019-2028 (US$ Million)
10.3.6.4.3 South Korea: Doxorubicin Market, By Application, 2019-2028 (US$ Million)
10.3.6.4.4 South Korea: Doxorubicin Market, By Distribution Channel, 2019-2028 (US$ Million)
10.3.6.5 Australia: Doxorubicin Market - Revenue and Forecast to 2028 (US$ Million)
10.3.6.5.1 Australia: Doxorubicin Market - Revenue and Forecast to 2028 (US$ Million)
10.3.6.5.2 Australia: Doxorubicin Market, By Drug Formulation, 2019-2028 (US$ Million)
10.3.6.5.3 Australia: Doxorubicin Market, By Application, 20192028 (US$ Million)
10.3.6.5.4 Australia: Doxorubicin Market, By Distribution Channel, 2019-2028 (US$ Million)
10.3.6.6 Rest of Asia Pacific: Doxorubicin Market - Revenue and Forecast to 2028 (US$ Million)
10.3.6.6.1 Rest of Asia Pacific: Doxorubicin Market - Revenue and Forecast to 2028 (US$ Million)
10.3.6.6.2 Rest of Asia Pacific: Doxorubicin Market, By Drug Formulation, 2019-2028 (US$ Million)
10.3.6.6.3 Rest of Asia Pacific: Doxorubicin Market, By Application, 2019-2028 (US$ Million)
10.3.6.6.4 Rest of Asia Pacific: Doxorubicin Market, By Distribution Channel, 2019-2028 (US$ Million)
10.4 South and Central America: Doxorubicin Market Revenue and Forecasts To 2028
10.4.1 Overview
10.4.2 South and Central America: Doxorubicin Market - Revenue and Forecast to 2028 (US$ Million)
10.4.3 South and Central America: Doxorubicin Market, by Drug Formulation, 2019-2028 (US$ Million)
10.4.4 South and Central America: Doxorubicin Market, by Application, 2019-2028 (US$ Million)
10.4.5 South and Central America: Doxorubicin Market, by Distribution Channel, 2019-2028 (US$ Million)
10.4.6 South and Central America: Doxorubicin Market, by Country, 2022 & 2028 (%)
10.4.6.1 Brazil: Doxorubicin Market - Revenue and Forecast to 2028 (US$ Million)
10.4.6.1.1 Overview
10.4.6.1.2 Brazil: Doxorubicin Market - Revenue and Forecast to 2028 (US$ Million)
10.4.6.1.3 Brazil: Doxorubicin Market, by Drug Formulation, 2019-2028 (US$ Million)
10.4.6.1.4 Brazil: Doxorubicin Market, by Application, 2019-2028 (US$ Million)
10.4.6.1.5 Brazil: Doxorubicin Market, by Distribution Channel, 2019-2028 (US$ Million)
10.4.6.2 Argentina: Doxorubicin Market - Revenue and Forecast to 2028 (US$ Million)
10.4.6.2.1 Overview
10.4.6.2.2 Argentina: Doxorubicin Market - Revenue and Forecast to 2028 (US$ Million)
10.4.6.2.3 Argentina: Doxorubicin Market, by Drug Formulation, 2019-2028 (US$ Million)
10.4.6.2.4 Argentina: Doxorubicin Market, by Application, 2019-2028 (US$ Million)
10.4.6.2.5 Argentina: Doxorubicin Market, by Distribution Channel, 2019-2028 (US$ Million)
10.4.6.3 Rest of South and Central America: Doxorubicin Market - Revenue and Forecast to 2028 (US$ Million)
10.4.6.3.1 Overview
10.4.6.3.2 Rest of South and Central America: Doxorubicin Market - Revenue and Forecast to 2028 (US$ Million)
10.4.6.3.3 Rest of South and Central America: Doxorubicin Market, by Drug Formulation, 2019-2028 (US$ Million)
10.4.6.3.4 Rest of South and Central America: Doxorubicin Market, by Application, 2019-2028 (US$ Million)
10.4.6.3.5 Rest of South and Central America: Doxorubicin Market, by Distribution Channel, 2019-2028 (US$ Million)
10.5 Middle East & Africa Doxorubicin Market
10.5.1 Overview
10.5.2 Middle East & Africa Doxorubicin Market Revenue and Forecast to 2028 (US$ Million)
10.5.3 Middle East & Africa: Doxorubicin Market, Revenue and Forecasts to 2028, By Drug Formulation (US$ Million)
10.5.3.1 Middle East & Africa: Doxorubicin Market, Revenue and Forecasts to 2028, By Application (US$ Million)
10.5.4 Middle East & Africa: Doxorubicin Market-Revenue and Forecasts to 2028, By Distribution Channel (US$ Million)
10.5.5 Middle East & Africa Doxorubicin Market Revenue and Forecast to 2028, by Country (%)
10.5.5.1 Saudi Arabia: Doxorubicin Market Revenue and Forecast to 2028 (US$ Million)
10.5.5.1.1 Saudi Arabia: Doxorubicin Market Revenue and Forecast to 2028 (US$ Million)
10.5.5.1.2 Saudi Arabia: Doxorubicin Market, Revenue and Forecasts to 2028, By Drug Formulation (US$ Million)
10.5.5.1.3 Saudi Arabia: Doxorubicin Market, Revenue and Forecasts to 2028, By Application (US$ Million)
10.5.5.1.4 Saudi Arabia: Doxorubicin Market-Revenue and Forecasts to 2028, By Distribution Channel (US$ Million)
10.5.5.2 South Africa: Doxorubicin Market Revenue and Forecast to 2028 (US$ Million)
10.5.5.2.1 South Africa Doxorubicin Market Revenue and Forecast to 2028 (US$ Million)
10.5.5.2.2 South Africa: Doxorubicin Market, Revenue and Forecasts to 2028, By Drug Formulation (US$ Million)
10.5.5.3 South Africa: Doxorubicin Market, Revenue and Forecasts to 2028, By Application (US$ Million)
10.5.5.3.1 South Africa: Doxorubicin Market-Revenue and Forecasts to 2028, By Distribution Channel (US$ Million)
10.5.5.4 UAE: Doxorubicin Market Revenue and Forecast to 2028 (US$ Million)
10.5.5.4.1 UAE: Doxorubicin Market Revenue and Forecast to 2028 (US$ Million)
10.5.5.4.2 UAE : Doxorubicin Market, Revenue and Forecasts to 2028, By Drug Formulation (US$ Million)
10.5.5.4.3 UAE : Doxorubicin Market, Revenue and Forecasts to 2028, By Application (US$ Million)
10.5.5.4.4 UAE : Doxorubicin Market-Revenue and Forecasts to 2028, By Distribution Channel (US$ Million)
10.5.5.5 Rest of Middle East & Africa: Doxorubicin Market Revenue and Forecast to 2028 (US$ Million)
10.5.5.5.1 Rest of Middle East & Africa: Doxorubicin Market Revenue and Forecast to 2028 (US$ Million)
10.5.5.5.2 Rest Of Middle East & Africa: Doxorubicin Market, Revenue and Forecasts to 2028, By Drug Formulation (US$ Million)
10.5.5.5.3 Rest Of Middle East & Africa: Doxorubicin Market, Revenue and Forecasts to 2028, By Application (US$ Million)
10.5.5.5.4 Rest Of Middle East & Africa: Doxorubicin Market-Revenue and Forecasts to 2028, By Distribution Channel (US$ Million)
11. Impact of COVID-19 Pandemic on Geographic Regions
11.1 North America: Impact Assessment of COVID-19 Pandemic
11.2 Europe: Impact Assessment of COVID-19 Pandemic
11.3 Asia Pacific: Impact Assessment Of COVID-19 Pandemic
11.4 Middle East & Africa: Impact Assessment of COVID-19 Pandemic
11.5 South And Central America: Impact Assessment Of COVID-19 Pandemic
12. Doxorubicin Market-Industry Landscape
12.1 Overview
12.2 Growth Strategies Done by the Companies in the Market, (%)
12.3 Organic Developments
12.3.1 Overview
12.4 Inorganic Developments
12.4.1 Overview
13. Company Profiles
13.1 Accord Healthcare
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Cipla Inc.
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Dr. Reddy's Laboratories
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Meiji Holdings Co., Ltd.
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Janssen Pharmaceuticals (Johnson & Johnson Services, Inc.)
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Novartis AG
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Pfizer Inc.
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Sun Pharmaceutical Industries Ltd
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 Baxter International Inc.
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Zydus Cadila
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. Appendix
14.1 About the Publisher
14.2 Glossary of Terms

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Accord Healthcare
  • Cipla Inc.
  • Dr. Reddy's Laboratories
  • Meiji Holdings Co., Ltd.
  • Janssen Pharmaceuticals (Johnson and Johnson Services, Inc.)
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd
  • Baxter International Inc.
  • Zydus Cadila